Keyphrases
Mantle Cell Lymphoma
100%
Drug Development
100%
DNA Methylation Analysis
100%
CD37
40%
Lymphoma Patients
20%
Lymphoma Cells
20%
Promoter Methylation
20%
Naïve B Cells
20%
Hypermethylated Genes
20%
MRNA Level
10%
Malignancy
10%
Lymph Node
10%
PCR Assay
10%
Histone Deacetylase Inhibitor (HDACi)
10%
Surface Expression
10%
Immunohistochemical Analysis
10%
Histone Deacetylase 1 (HDAC1)
10%
Cytotoxicity
10%
Methylation
10%
Significant Loss
10%
Patient Samples
10%
Aberrant Methylation
10%
DNA Methyltransferase Inhibitor
10%
Aberrancy
10%
Lymphoma Therapy
10%
Hypomethylating Agents
10%
Notch1
10%
Methylation Pattern
10%
Therapeutic Benefits
10%
Cyclin-dependent Kinase 5 (Cdk5)
10%
Statistical Criteria
10%
Ligation-mediated PCR
10%
Decitabine
10%
CDKN2B
10%
HOXD8
10%
Viability Loss
10%
Suberoylanilide Hydroxamic Acid
10%
Differentially Methylated Genes
10%
HpaII
10%
Mantle Zone
10%
Aberrant Hypermethylation
10%
PCDH8
10%
Small Modules
10%
Biochemistry, Genetics and Molecular Biology
Methylation
100%
DNA Methylation
100%
Methylation Analysis
100%
Drug Development
100%
Promoter Region
50%
Naive B Cell
50%
Cytotoxicity
25%
DNA Methyltransferase
25%
Histone Deacetylase
25%
Decitabine
25%
HDAC1
25%
CDKN2B
25%
Small Modular Immunopharmaceutical
25%
Messenger RNA
25%
Medicine and Dentistry
Mantle Cell Lymphoma
100%
DNA Methylation
100%
Methylation
50%
B Cell
25%
Promoter Region
25%
Mantle Cell Lymphoma Cell Line
25%
Cancer
12%
Ligation
12%
Lymph Node
12%
Cell Line
12%
Vorinostat
12%
Histone Deacetylase Inhibitor
12%
Cytotoxicity
12%
Decitabine
12%
HDAC1
12%
DNA Methyltransferase Inhibitor
12%
Mantle Zone
12%
Messenger RNA
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
100%
Drug Development
100%
Histone Deacetylase Inhibitor
10%
Decitabine
10%
Histone Deacetylase 1
10%
Vorinostat
10%
DNA Methyltransferase Inhibitor
10%
Messenger RNA
10%
Cytotoxicity
10%